GLP-1 Medication Cost Calculator

Ozempic (semaglutide) was historically very expensive at ~$935/month list price. However, in early 2026, the Trump administration’s MFN pricing deals with Novo Nordisk dramatically reduced costs. Self-pay Ozempic is now $499/month through NovoCare, with a $199/month introductory offer for new patients. The TrumpRx program will offer it at $350/month. Medicare patients pay approximately $245/month. While still not cheap, it’s nearly half the previous cost.

Coverage has expanded significantly in 2026. Most commercial insurance plans cover all four major GLP-1 medications. The biggest change: Medicare Part D now covers Wegovy and Zepbound for obesity, not just diabetes. This is a major shift — previously, Medicare only covered Ozempic and Mounjaro for type 2 diabetes. Medicare patients can expect to pay approximately $245/month. Medicaid coverage varies by state but is expanding. Always check your specific formulary and be prepared to go through prior authorization.

Compounded semaglutide is no longer legally available after the FDA resolved the shortage in late 2024. The good news: brand-name prices have dropped so much in 2026 that the cost gap has nearly closed. Self-pay Wegovy is now $499/month (vs $150–$300 for compounded), and the new oral Wegovy pill starts at just $149/month for the first two months. The TrumpRx program will bring injectable prices down to $350/month. If you were using compounded semaglutide, brand-name options are now far more affordable than before.

Potentially, yes. Both Novo Nordisk and Eli Lilly offer patient assistance programs (PAPs) for uninsured patients who meet income guidelines. Through NovoCare and Lilly Cares, qualifying patients can receive their medication at no cost. Additionally, some commercially-insured patients can use manufacturer savings cards to reduce copays to $0. Wegovy’s savings card program, for example, has offered $0 copays for eligible patients with commercial insurance. However, these programs have eligibility requirements and enrollment periods, so check each manufacturer’s website for current availability.

No, not yet. Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are both protected by patents that extend into the early-to-mid 2030s. Because these are complex biologic drugs (not simple chemical compounds), even when patents expire, we’ll see “biosimilars” rather than traditional generics — and biosimilars typically launch at only 15–30% below brand prices. Meaningful price competition from generics or biosimilars is likely still 8–10+ years away. In the meantime, the strategies listed above — savings cards, insurance optimization, and patient assistance programs — are the best ways to manage costs.

As of February 2026, the new oral Wegovy pill is the most affordable at $149/month intro pricing (first 2 months), then $349/month. For injectables, Ozempic and Wegovy are both $499/month self-pay through NovoCare, while Zepbound starts at $499/month and Mounjaro at $599–$699/month through LillyDirect. New patients can get $199/month intro pricing on Ozempic/Wegovy through March 31, 2026. With commercial insurance and a savings card, all medications can potentially cost $0–$25/month. Medicare patients now pay approximately $245/month for any of these medications. Use our calculator above to find the cheapest option for your specific situation.